(CMRG)-008: A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM (clinicaltrials.gov) - Oct 23, 2026 - P2 | N=72 | Active, not recruiting | Sponsor: Canadian Myeloma Research Group | Trial completion date: Jun 2027 ➔ Dec 2028 | Trial primary completion date: Mar 2026 ➔ Dec 2028
Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation
|